Expertise in
39
conditions

Dr. Marc R. Matrana

Oncology
1514 Jefferson Highway, 
New Orleans, LA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
39
conditions
1514 Jefferson Highway, 
New Orleans, LA 

Overview

Marc Matrana is an Oncologist practicing medicine in New Orleans, Louisiana.

Dr. Matrana is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Lung Cancer, Adult Soft Tissue Sarcoma, and Nephrectomy.

Dr. Matrana is board certified in American Board Of Internal Medicine - Hematology/Oncology and American Board Of Internal Medicine - Internal Medicine. He is actively involved in clinical research, co-authoring 71 peer reviewed articles and participating in 43 clinical trials. Dr. Matrana is currently accepting new patients.

Specialties

Oncology

Licenses

Hospitalist in LA

Board Certifications

American Board Of Internal Medicine - Hematology/Oncology
American Board Of Internal Medicine - Internal Medicine

Fellowships

MD Anderson Cancer Center, Hematology/Oncology
Year Completed: 2013

Hospital Affiliations

Ochsner St Anne General Hospital
Ochsner Medical Center Acute
Slidell Memorial Hospital
Ochsner Medical Center-Kenner
Ochsner Medical Center - Baton Rouge

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Ochsner Medical Center - New Orleans
1514 Jefferson Highway, New Orleans, LA 70121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

43 Clinical Trials

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: August 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
View 9 Less Clinical Trials

71 Total Publications

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.
Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.
Journal: Expert opinion on biological therapy
Published: August 29, 2026
Similar Doctors
Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

Ochsner Clinic Foundation

1514 Jefferson Hwy, 
New Orleans, LA 
 (0.1 miles away)
504-842-3910
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Cole is an Oncologist practicing medicine in New Orleans, Louisiana. Dr. Cole is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Bone Marrow Aspiration, and Endoscopy. Dr. Cole is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Tulane University School Of Medicine

1430 Tulane Ave, 
New Orleans, LA 
 (4.1 miles away)
504-988-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hana Safah is an Oncologist practicing medicine in New Orleans, Louisiana. Dr. Safah is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Bone Marrow Aspiration. Dr. Safah is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

St. Tammany Cancer Center - A Campus Of Ochsner Medical Center

900 Ochsner Blvd, 
Covington, LA 
 (33.8 miles away)
985-249-2383
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patricia Braly is an Oncologist practicing medicine in Covington, Louisiana. Dr. Braly is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Cervical Cancer, and Ovarian Carcinosarcoma. Dr. Braly is board certified in American Board Of Obstetrics And Gynecology - Medical Oncology and American Board Of Obstetrics And Gynecology - Obstetrics & Gynecology. Dr. Braly is currently accepting new patients.

Frequently Asked Questions about Dr. Marc R. Matrana

How do I make an appointment with Dr. Marc R. Matrana?

You can book an appointment with Dr. Marc R. Matrana by calling their office at 504-842-3910. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Marc R. Matrana a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Marc R. Matrana is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Marc R. Matrana specialize in?

While Dr. Marc R. Matrana is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Urothelial Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Marc R. Matrana participate in research or clinical trials?

Yes. Dr. Marc R. Matrana has published 71 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Marc R. Matrana's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Marc R. Matrana accept my insurance?

Dr. Marc R. Matrana accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 504-842-3910 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Matrana's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 31 Advanced Conditions
View All 58 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile